Health Care | Pharmaceuticals and Biotechnology

GENE 5 Dimension Analysis

Analysis Instruction of GENE

  1. Due to insufficient company valuation data, it is not possible to provide a rating.
    2. The current stock trend is in a consolidation phasewith strongest momentum accumulation in the intermediate-term.
    3. The current potential for an upward price swing is lower, awaiting a swing trading score of 4 or above.
    4. No dividend history, not ideal for dividend-oriented buy-and-hold strategy.

Performance

1D1M3M6M1Y
GENE0.97%-8.88%-7.32%-33.62%-34.07%
Avg of Sector-0.33%-7.78%-12.89%-9.97%-14.44%
S&P 5000.01%-5.04%-3.64%4.36%19.60%

Price of GENE